COPCOV trial resumes in the UK


The Diabetes Trials Unit is resuming the COPCOV trial in the UK following renewed approval from UK regulators.

This important global trial will answer the question whether health-care workers who take hydroxychloroquine, compared with a placebo, will have lower risk of getting COVID-19. COPCOV, which is a prevention rather than a treatment trial, will enrol healthcare workers from across the UK.

MHRA approval

[Health care workers can register your interest here]